BCM
BIOTU

BCK Capital Management’s Biotech Acquisition Company Unit BIOTU Stock Holding History

BCK Capital Management’s Portfolio BIOTU Stock Details BIOTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-27,146
Closed -$275K – 162
2021
Q4 		$275K Buy
27,146
+416
+2% +$4.21K 0.19% 102
2021
Q3 		$268K Hold
26,730
– – 0.16% 122
2021
Q2 		$269K Hold
26,730
– – 0.13% 120
2021
Q1 		$264K Buy
+26,730
New +$275K 0.15% 125

Other funds holding BIOTU

HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
LCM
Landscape Capital Management Englewood, New Jersey $1.58B AUM 26.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SIA
SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BCK Capital Management's BIOTU Position: Q1 2022 in Review

BCK Capital Management sold out of Biotech Acquisition Company Unit (BIOTU) in Q1 2022, closing a stake of 27,146 shares — an estimated $275K sold.

BCK Capital Management first reported a position in BIOTU in Q1 2021 and held it in 4 quarters. The position peaked at $275K in Q4 2021. 10 funds tracked by Wall St. Rank hold BIOTU as of Q1 2022.

  • BCK Capital Management reported no remaining Biotech Acquisition Company Unit position as of Q1 2022 after selling out during the quarter.
  • BCK Capital Management sold 27,146 Biotech Acquisition Company Unit shares in Q1 2022, an estimated $275K.
  • BCK Capital Management first reported a position in Biotech Acquisition Company Unit in Q1 2021 and held it in 4 quarters.
  • BCK Capital Management's Biotech Acquisition Company Unit position peaked at $275K in Q4 2021.
  • 10 funds tracked by Wall St. Rank held Biotech Acquisition Company Unit as of Q1 2022.

Based on BCK Capital Management's 13F filing for Q1 2022, filed 5 May 2022.